As the need to draw awareness to cervical, ovarian, uterine/endometrial, vaginal, and vulvar cancer becomes more evident, ...

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high expectations from early-phase studies, the drug initially did not meet the ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

Bianca Balti has been diagnosed with ovarian cancer.

September is Ovarian Cancer Awareness Month, focusing on raising awareness, improving early detection, and supporting ...

Dr. Diego Aviles with UT Physicians says symptoms of ovarian cancer typically include bloating, pain in the stomach or pelvis ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

Ovarian cancer is a type of cancer that impacts the female reproductive system. The risk of developing ovarian cancer in a woman's lifetime is 1 in 87, according to the American Cancer Society (ACS).

New research identifies specific genetic changes that can increase a person's risk of breast and ovarian cancers, to help guide clinical decision-making.

According to the American Cancer Society, one of the leading causes for cancer deaths among women is ovarian cancer. While ...

Scientists have pinpointed thousands of genetic changes in a gene that may increase a person's risk of developing breast and ...